The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Oct 2005
Randomized Controlled Trial Clinical TrialEffect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.
Very late antigen (VLA-4) antagonists have been proposed as potential therapies for diseases in which cell recruitment and accumulation are causative. Asthma, which is characterized by airway inflammation involving the accumulation of eosinophils and mononuclear cells, is one such disease. ⋯ In patients with mild-to-moderate atopic asthma, IVL745 did not affect the early and late response to inhaled allergen or markers of airway inflammation, except for a modest reduction in sputum eosinophils.